Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management BoardGuruFocus · Oct 15, 2026
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management BoardPRNewsWire · Oct 15, 2026
Evotec (NASDAQ:EVO) Sees Unusually-High Trading Volume – Time to Buy?Defense World · Sep 30, 2026
Evotec Announces Chief Scientific Officer TransitionGuruFocus · Sep 29, 2026
Evotec Announces Chief Scientific Officer TransitionPRNewsWire · Sep 29, 2026
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 CongressBusiness Wire · Sep 23, 2026Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.05 | -$0.17 | Miss |
| May 6, 2026 | -$0.15 | -$0.46 | Miss |
| Apr 8, 2026 | $0.21 | $0.05 | Miss |
| Nov 5, 2025 | -$0.14 | -$0.14 | Miss |
| Aug 13, 2025 | -$0.18 | -$0.14 | Beat |
| May 6, 2025 | -$0.11 | -$0.15 | Miss |